6-K
ASTRAZENECA PLC (AZN)
FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Report of Foreign Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For the month of March 2026
Commission File Number: 001-11960
AstraZeneca PLC
1 Francis Crick Avenue
Cambridge Biomedical Campus
Cambridge CB2 0AA
United Kingdom
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F X Form 40-F __
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes __ No X
If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_____________
AstraZeneca PLC
INDEX TO EXHIBITS
1. Notification of Admission of Shares
20 March 2026
Notification of Admission of Further Securities to Trading (PRM 1.6.4R)
AstraZeneca PLC (the Company) announced today the following information in accordance with The Public Offers and Admissions to Trading Regulations 2024 (POATRs) PRM 1.6.4R.
| 1 | Details of the issuer | |
|---|---|---|
| a) | Name | AstraZeneca PLC |
| b) | LEI | PY6ZZQWO2IZFZC3IOL08 |
| 2 | Details of the transferable securities admitted to<br>trading | |
| a) | Name, type and identification code | Ordinary Shares of $0.25 each<br><br><br><br><br><br>ISIN: GB0009895292 |
| b) | Regulated market | London Stock Exchange - Main Market |
| c) | Number of further securities issued and admitted | 45,750 |
| d) | Total number of securities in issue following<br>admission | 1,550,980,332 |
| e) | Fungibility | Fully fungible with existing Ordinary Shares |
| 3 | Admission details | |
| a) | Date of admission | Issued between 20 January 2026 to 19 March 2026 (admitted under a<br>block admission dated 29<br>January 2021) |
| b) | Prospectus information | Prospectus: N/A<br><br><br><br><br><br>Supplementary: N/A<br><br><br><br><br><br>Company's webpage: https://www.astrazeneca.com |
| c) | Coverage of notification | Admission of shares under the Company's employee share schemes from<br>20 January 2026 up to 19 March 2026, admitted to trading on the<br>Main Market of the London Stock Exchange under the Company's<br>existing block admission of shares dated 29 January<br>2021. |
AstraZeneca
AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on social media @AstraZeneca
Contacts
For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.
Matthew Bowden
Company Secretary
AstraZeneca PLC
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| AstraZeneca<br>PLC |
|---|
Date: 20 March 2026
| By: /s/<br>Matthew Bowden |
|---|
| Name:<br>Matthew Bowden |
| Title:<br>Company Secretary |